ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using our proprietary discovery platform for targeted (epitope-specific) immunotherapy, ImmusanT is developing a therapy and personalized diagnostics for celiac disease and is expanding to other autoimmune diseases including Type 1 diabetes.
We are now recruiting for clinical trials in celiac disease.
September 11, 2017
ImmusanT Presents Data from Multiple Studies Supporting Continued Development of Nexvax2®
August 31, 2017
Leading Immunologists Gather in New Delhi to Confront Celiac Disease
May 12, 2017
ImmusanT Announces Publication of Positive Data from Phase 1 Trials of Nexvax2 in Celiac Disease Patients
May 8, 2017
ImmusanT Reports Data on Novel Celiac Disease Diagnostic Approach
One Kendall Square
Suite B2004
Cambridge, MA 02139
Phone: 617-299-8399